Síbus

Quick links to important sections

Síbus

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Síbus

Property Description
Active ingredient Sibutramine
Form Oral Capsule
Pharmacological class Centrally acting appetite suppressant
Common use Adjunctive treatment for exogenous obesity
Origin Synthetic compound

Defining the Core Identity

Síbus is a prescription-only medication primarily used to support weight management, with Sibutramine as its active ingredient. This drug is a synthetic compound derived from the substituted amphetamine chemical family, classifying it as an anorectic agent—a substance that suppresses appetite by acting on the central nervous system. This distinct identity restricts its use to medical supervision, distinguishing it from non-prescription supplements.

Sibutramine: Composition and Pharmacological Class

The medication is supplied as an oral capsule, positioning it as an orally available form for systemic action. As a single-ingredient product (monotherapy), it contains Sibutramine hydrochloride monohydrate. Pharmacologically, Sibutramine is categorized as a Serotonin-Norepinephrine-Dopamine Reuptake Inhibitor (SNDRI), a classification defined in its chemical profile. This unique designation reflects its high-level mechanism of modulating monoamine activity in the brain regions that control hunger and fullness.

The General Purpose of This Appetite Suppressant

The general purpose of Síbus is to assist adult patients who are diagnosed with exogenous obesity, typically defined by specific body mass index (BMI) thresholds, especially when associated with coexisting health risk factors. The drug's mechanism enhances satiety (fullness) and reduces overall hunger, which is clinically supported as a means to facilitate a reduction in daily caloric intake. This action is intended to support the patient’s commitment to the necessary dietary changes and increased physical activity crucial for successful therapeutic weight management.

What side effects are possible with Síbus?

Possible Side Effects and Safety Information

Medicines containing sibutramine, such as Síbus, have an officially documented safety profile characterized by cardiovascular risks and effects on the central and peripheral nervous systems, as detailed in regulatory documents.


Common Adverse Reactions

Adverse reactions classified as Common (affecting ge 1 in 100 users) in official prescribing information primarily affect the following systems:

System-Organ Class (SOC) Key Official Adverse Reactions
Nervous System Headache, dry mouth, insomnia, nervousness
Gastrointestinal Constipation, anorexia, nausea
Vascular/Cardiac Increased heart rate (Tachycardia), increased blood pressure (Hypertension)

Serious Adverse Reactions and Safety Constraints

The most significant safety constraint documented by regulatory authorities is the risk of Major Adverse Cardiovascular Events (MACE), including non-fatal myocardial infarction (heart attack) and non-fatal stroke. Other serious reactions listed include cases of Serotonin Syndrome and infrequently reported seizures.

Use is contraindicated in specific patient populations due to documented risks, including those with a history of coronary artery disease, congestive heart failure, or stroke. It is also not recommended for use in patients with severe hepatic dysfunction, severe renal impairment, or those with uncontrolled hypertension. The label requires mandatory and frequent monitoring of blood pressure and pulse rate throughout the period of administration, reflecting the drug's physiological effects on the vascular system.

Overdose and Emergency Response

Overdose and When to Seek Help

The following information is based strictly on documented regulatory guidance regarding an overdose of sibutramine (Síbus). This section explains the official symptoms, emergency procedures, and supportive measures required in an overdose situation.

Documented Overdose Presentations

Official regulatory documents note that acute overdose with sibutramine may lead to an exaggeration of its known pharmacological effects. Symptoms reported in overdose cases include:

System Documented Manifestations
Cardiovascular Tachycardia (increased heart rate), Hypertension (high blood pressure)
Central Nervous System Headache, Dizziness

Serious Outcomes and Emergency Action

Overdose has the potential for serious or life-threatening cardiovascular events, including those identified in regulatory safety warnings, such as non-fatal myocardial infarction and stroke. There is no specific pharmacological antidote for sibutramine overdose.

Immediate medical attention must be sought if an overdose is suspected or if severe symptoms occur. Regulatory guidance emphasizes that in all overdose situations, treatment must be supportive and symptomatic. This includes establishing a clear airway and continuous monitoring, particularly of the cardiovascular system. In the event of suspected overdose, calling a poison control center or seeking emergency medical care is explicitly required.

Therapeutic Uses of Síbus

What Síbus Treats: Main Uses and Benefits

Síbus is commonly used in the symptomatic management of exogenous obesity in adult patients with elevated Body Mass Index (BMI) ge 30 kg/m^2, or in patients classified as overweight (BMI ge 27 kg/m^2) who may experience related health issues such as Type 2 diabetes or dyslipidemia. This intervention is considered relevant when supportive symptom management is needed alongside dietary changes.

The medication is applied across domains where additional symptomatic support is needed, specifically addressing the core symptomatic cluster of disordered appetite control. This involves managing persistent, intense hunger and the lack of a feeling of fullness (satiety). The medication may assist with maintaining functional stability, which helps patients cope more steadily with their medically prescribed, reduced-calorie diet, which is relevant for the clinical objective of weight maintenance and the support of associated health risk management.

“The medication is commonly used to help with the management of appetite, which supports general well-being during symptomatic phases.”

Quick Fact: Relevant for Easing Symptom Clusters

Eligibility and Restrictions for Use

Who Can and Cannot Use Síbus?

Eligibility for Síbus (Sibutramine) is determined by strict official guidelines, primarily based on patient demographics and pre-existing health conditions documented in regulatory labeling. This information is non-advisory and defines who is permitted and who is prohibited from using the medicine.


Eligibility and Exclusion Status

Status Population / Condition Regulatory Criteria
Permitted Use Adults (18–65 years) Must meet BMI ge 30 kg/m^2, or BMI ge 27 kg/m^2 with Type 2 diabetes or dyslipidemia.
Not Recommended Children/Adolescents (under 18) Safety and efficacy not established.
Not Recommended Older Adults (over 65) Clinical experience is limited.
Contraindicated Pregnancy and Lactation Use is strictly prohibited.

Absolute Contraindications

Síbus is strictly contraindicated for use in populations with certain serious medical conditions, as defined by regulatory authorities. These include a history of or current Major Cardiovascular Disease (e.g., coronary artery disease, stroke, uncontrolled hypertension) and conditions such as Severe Hepatic or Renal Impairment, Hyperthyroidism, and Serious Eating Disorders (e.g., Anorexia, Bulimia).

What should I know about interactions with other medicines?

Síbus Interactions with other medicines and products

Official regulatory documents define the interaction profile of Síbus (Sibutramine) based on critical pharmacokinetic and pharmacodynamic constraints. These constraints strictly govern which substances may or may not be administered concomitantly.

Interaction-Related Restrictions

Classification Interacting Agents Official Constraint Context
Contraindicated Monoamine Oxidase Inhibitors (MAOIs) Prohibited for co-administration or use within two weeks of stopping/starting Sibutramine.
Contraindicated Other Centrally-Acting Appetite Suppressants Prohibited from concurrent use due to heightened risk of adverse effects.
Caution Required Serotonergic Agents Co-administration with Tryptophan or other serotonergic drugs (e.g., SSRIs, SNRIs) may increase the risk of serious interaction.

Documented Pharmacokinetic Interactions

Sibutramine is primarily metabolized by the CYP3A4 enzyme to form active metabolites ( M1 and M2). Inhibitors of this enzyme, such as Ketoconazole and Erythromycin, have been officially documented to reduce the clearance of these active metabolites, leading to an increase in their systemic exposure ( AUC).

Other Documented Interactions

  • Sympathomimetics: Use with medications that can elevate blood pressure or heart rate (e.g., Ephedrine, Pseudoephedrine) should be avoided due to the risk of additive cardiovascular effects.
  • Food: Administration with food has been documented to decrease the rate of absorption ( C max) but does not significantly alter the overall systemic exposure ( AUC) of the active metabolites.
  • Population Note: While moderate hepatic impairment was shown to increase metabolite exposure, this difference did not officially warrant a dosage adjustment. Use in severe hepatic dysfunction is not recommended due to a lack of clinical data.

Mechanism of Action

How Síbus Works

Síbus is an oral small molecule that achieves selective localization within the skeletal system, concentrating specifically in the bone microenvironment. Its primary action is defined by a high-affinity interaction with the A1 receptor present on the surface of bone cells. This binding initiates an intracellular cascade that results in the modulation of Wnt signaling pathway activity, a critical regulator of bone cell fate.

The downstream effect of this modulation is the inhibition of osteoclast precursor differentiation and a reduction in the functional activity of mature osteoclasts. Simultaneously, the mechanism promotes the proliferation and activity of osteoblasts, the bone-forming cells. This dual effect ultimately results in the rebalancing of the cellular proliferation and differentiation rates, thereby shifting the equilibrium toward net bone deposition within the skeletal remodeling unit.

Dosage and Administration Information

Síbus is approved for use via the oral route only, supplied in capsule strengths of 5 mg, 10 mg, and 15 mg. The medication is designed to be taken once daily and may be administered with or without food. This once-daily frequency establishes the standard schedule for its use.

The regimen typically commences with an initial dose of 10 mg taken once daily. The official instruction set permits a dose adjustment to the maximum of 15 mg once daily only if the weight loss response is deemed inadequate after four weeks of treatment at the starting dose. A lower 5 mg dose may be considered for patients who do not tolerate the 10 mg starting dose. Patients who miss a scheduled dose should resume the routine the following day without taking a double dose to compensate.

Síbus is strictly defined as an adjunctive therapy, meaning its use is constrained to complement a comprehensive weight management program that includes a reduced-calorie diet and increased physical activity. The overall course of treatment should not typically exceed 12 months (one year). Furthermore, its continued administration is dependent on achieving a defined clinical response; clinical protocols stipulate discontinuation if the weight loss criteria are not met within specific timeframes. Usage is restricted for certain populations; for instance, prescribing guidelines contraindicate or do not recommend its use in patients over 65 years of age or those with severe hepatic or renal impairment. These principles define the standardized usage protocol for this oral capsule.

Recent Clinical Evidence

Síbus (Sibutramine) was evaluated in clinical trials as an adjunct to diet and exercise programs for weight management. Evidence from placebo-controlled trials has examined its influence on body weight and metabolic markers.

Efficacy Findings

Randomized controlled trials (RCTs) suggested that the use of Síbus was associated with greater weight loss compared to placebo in obese adults. A systematic review of trials lasting up to one year reported the following average mean differences in weight loss (Síbus minus placebo):

Trial Duration Mean Difference in Weight Loss 95% Confidence Interval
3 Months -2.78 kg -3.29 kg to -2.26 kg
1 Year -4.45 kg -5.29 kg to -3.62 kg

Trial data also suggested that continued therapy may be associated with the maintenance of weight reduction over a two-year period in some participants.

Cardiovascular Safety Profile

A major long-term trial, the SCOUT trial, evaluated cardiovascular outcomes in patients with pre-existing cardiovascular disease and/or type 2 diabetes. The study reported that the Síbus group was associated with a 16% increased relative risk of major adverse cardiovascular events (including non-fatal heart attack and stroke) compared to the placebo group.

Due to this finding, regulatory bodies in several major markets recommended the withdrawal of the drug from the market in 2010. Síbus was also associated with small, persistent increases in mean heart rate and blood pressure, necessitating regular monitoring during treatment in those countries where it remained available. Common reported side effects included dry mouth, insomnia, and constipation.

Key Studies & References The efficacy and safety of sibutramine for weight loss: a systematic review (CRD Summary)

Frequently Asked Questions (FAQ)

Common questions about Síbus (FAQ)


Q: How quickly does Síbus start working for people?

Official product information suggests that your clinical response should be assessed early in the treatment period. Regulatory labels require that the weight loss response be evaluated after the first four weeks of treatment to help determine the course of therapy.


Q: Is Síbus considered a type of antibiotic, or something else?

No, Síbus is not an antibiotic. According to official regulatory information, it is a prescription medicine classified as a Centrally Acting Appetite Suppressant. Its active ingredient works by modulating specific chemicals in the brain to help manage hunger and satiety.


Q: Do you have to take Síbus forever, or just for a short time?

Síbus is intended for short-term use as an adjunctive treatment within a comprehensive weight management program that includes diet and exercise. Official prescribing information states that the overall course of treatment should not typically exceed 12 months (one year).


Q: Is it normal to feel a bit nauseous when you first start taking Síbus?

Nausea is officially documented as a common adverse reaction for this medicine in regulatory product labeling. Experiencing nausea is a side effect that may warrant a discussion with a healthcare provider.


Q: What's the main difference between Síbus and a probiotic?

Síbus is a synthetic prescription medicine that acts on the central nervous system (the brain) to suppress appetite and aid in weight management. A probiotic, by contrast, is a live microorganism intended to promote the health of the gut and is not classified as a prescription drug.


Q: What if I accidentally miss a dose of Síbus—what should I do?

Official instructions state that if a scheduled dose is missed, treatment should resume the routine the following day. Regulatory labels advise against taking a double dose to compensate for a missed dose.


Q: What are the signs that Síbus is actually working for me?

The effectiveness of the treatment is measured by specific clinical response criteria. Continuation of use depends on the assessment that a defined clinical response is achieved, which includes meeting specific weight loss criteria within a set timeframe, such as the first four weeks.


Q: Is there a specific time of day that is best for taking Síbus?

Síbus is designed to be taken once daily and may be administered with or without food. It is often taken in the morning, which may help mitigate the potential for the side effect of insomnia.


Q: Is Síbus used for chronic conditions, or acute problems?

The medication is indicated as an adjunctive treatment for exogenous obesity. This condition is generally classified as a chronic (long-term) medical issue, and the treatment is intended to support ongoing management.


Q: Does Síbus have a strong impact on gut health?

Síbus is officially associated with common adverse reactions affecting the gastrointestinal system. These reported effects include constipation, anorexia (loss of appetite), and nausea.


Q: How does Síbus physically work inside the body?

For the purpose of weight management, Síbus works primarily in the brain. It is classified as a Serotonin-Norepinephrine-Dopamine Reuptake Inhibitor (SNDRI) that helps to enhance feelings of fullness (satiety) and reduce overall hunger.


Q: Is there a risk of weight change (gain or loss) while on Síbus?

Síbus is indicated to support weight loss. Loss of appetite (anorexia) is also a commonly reported side effect. Therapy is discontinued if the drug does not achieve the required weight loss criteria.


Q: Can Síbus affect mood or cause anxiety?

Adverse reactions affecting the nervous system are officially documented as common. These reported effects include nervousness and insomnia (difficulty sleeping).


Q: Why do some people say Síbus helps with their energy levels?

Some clinical studies have suggested that the active ingredient in Síbus may contribute to an increase in energy expenditure (thermogenesis). This physiological change is what patients may perceive as an increase in their overall energy levels.


Q: Has Síbus been studied in older adults (seniors)?

Official regulatory information states that the use of Síbus in older adults, specifically patients over 65 years of age, is not recommended. This is due to the limited amount of clinical experience available for this population.


Q: Is Síbus available in generic form, or only brand name?

The active ingredient in Síbus, sibutramine hydrochloride monohydrate, has been approved by regulatory bodies for use under both its original brand name and as a generic drug.


Q: Can Síbus cause any changes to my sleep patterns?

The product label documents insomnia (trouble falling or staying asleep) as a common adverse reaction. This is considered a change in a person’s normal sleep pattern.


Q: Is Síbus safe for teenagers to take?

Official prescribing information states that the use of Síbus in children and adolescents (under 18 years of age) is not recommended. This is because the safety and effectiveness of the medication have not been established in this age group.


Q: Is it okay to crush or chew the Síbus tablet, or must it be swallowed whole?

Síbus is supplied as an oral capsule and is typically intended to be swallowed whole. General regulatory guidance for this type of formulation usually advises against crushing or chewing the capsule.


Q: Does Síbus affect liver function tests?

Regulatory documents note that abnormal results for liver function tests, specifically increases in liver enzymes (ALT and AST), have been reported as adverse events during clinical trials.


Q: Are there any specific warnings about driving or operating machinery while on Síbus?

Because of its effects on the central nervous system (CNS), which can include dizziness and nervousness, patients should use caution. Official documents advise exercising care when performing hazardous tasks, such as driving a car or operating heavy machinery.


Q: What should I do if my side effects from Síbus seem worse than expected?

In the event of severe or concerning symptoms, such as pain in the chest, heart palpitations, or severe dizziness, regulatory safety communications note that the onset of such symptoms warrants immediate professional medical attention.


Q: Can Síbus be taken at the same time as my other morning medications?

Síbus is taken once daily, but it has a significant drug-interaction profile. The safety of co-administration with other morning medications requires review by a healthcare provider due to the potential for adverse interactions.

How should Síbus be stored and disposed of?

The storage and disposal of Síbus (sibutramine hydrochloride monohydrate) must adhere to official regulatory conditions to ensure product quality and safety.

Storage Conditions

Requirement Details
Temperature Store at Controlled Room Temperature between 20 C and 25 C (68 F to 77 F).
Protection Must be protected from excessive humidity and light; do not refrigerate or freeze.
Container Keep in the original container and ensure the cap is tightly closed.
Child-Safety Store strictly out of the sight and reach of children.

Disposal Instructions

Unused or expired Síbus should primarily be disposed of through an authorized drug take-back program or mail-back service. If unavailable, mix the medicine with an undesirable substance, seal it in a bag, and place it in the household trash; do not flush down the toilet or sink. All personal information on the packaging must be removed or defaced before discarding.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Síbus found in:

A-Z Index: